1. Introduction {#s0005}
===============

The seeds of the medicinal plant *Nigella sativa* L. (NS) are commonly used as a spice known as black seed. It also has traditional medical applications and considered to be a characteristic traditional herbal medicine for diverse diseases in Unani, Arabic, Prophetic and Indian traditional medicines ([@b0020]). Popular ancient physicians such as Hippocrates (460--370 BCE), Dioscorides (40--90 CE), Galen (130--210 CE), and Avicenna (980--1037 CE) reported various traditional therapeutic uses of NS ([@b0085]).

In the context of bronchial asthma and its symptoms, the Muslim scholar Imam Ibn Qayyim Al-Jawziyya (1292--1350 CE), author of the Prophetic Medicine, reported that NS aid in gasping and hard breathing ([@b0015]). Avicenna has also reported its benefit for shortness of breath (انتصاب النفس) and for stopping phlegm (مقطع البلغم) ([@b0050]). Nowadays, NS is still a traditional remedy for many illnesses such as cough and asthma in Arabia ([@b0160]).

The chemical composition of NS has been studied in considerable detail. Mainly, it contains fixed oil (24.76--40.35%), volatile oil (0.5--1.6%), alkaloids, saponins, and other compounds in trace amounts ([@b0020], [@b0085], [@b0165]). The activity of NS appeared to be mainly attributed to thymoquinone ([@b0020]). Thymoquinone was first isolated from NS oil by [@b0100].

The Global Initiative for Asthma defined asthma as "a heterogeneous disease, usually characterised by chronic airway inflammation. It is identified by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation" ([@b0125]). The Global Asthma Report 2014 considered asthma as an epidemic disease probably affecting about 334 million people worldwide and becoming a global health priority ([@b0120]). In Saudi Arabia (with a population of 28 million), the prevalence of asthma is increasing and affects more than 2 million Saudis ([@b0035]).

Asthma is initiated by multiple interactions between inflammatory cells and mediators. After an exposure to a triggering factor, inflammatory mediators are released from mast, macrophages, T-cells and epithelial cells. This cause attraction of other inflammatory cells mainly eosinophil into the pulmonary tissues. These causes lung injury, mucus hypersecretion and smooth muscle hyperactivity. Furthermore, at least 27 cytokines and 18 chemokines play a role in asthma pathophysiology ([@b9025]). Th2 lymphocytes cytokines \[interleukin IL-4, IL-5, and IL-13\] and Th1 cytokine interferon-gamma are the main ones to provoke allergy and asthma ([@b9035]).

Generally, the key goals for asthma management are to reach a good control of symptoms and minimize future risk of exacerbations, airflow limitation and treatment adverse events. Assessment of asthma control level can be done using several tools ([@b0060]). The Asthma Control Test (ACT) is a global validated numerical tool for the assessment of asthma control which is also commonly used by health care providers in Saudi Arabia ([@b0035]). Future risk can be assessed by pulmonary function testing, particularly the forced expiratory volume in one second (FEV1) ([@b0060]).

From a global clinical perspective, achieving asthma control is considered to be suboptimal regardless of the availability of conventional treatments ([@b9005], [@b9040]). Poor adherence to asthma medications is one of the factors leading to suboptimal asthma control ([@b9015], [@b9020]). Common medication-related reasons for non-adherence include difficulties with inhaler techniques, the complex course of therapy, adverse events, and cost of medications ([@b0060], [@b9010]). In Saudi Arabia, a survey of adult asthmatics found that asthma attacks were highly associated with patients on current asthma medications ([@b0175]). The Global Asthma Physician and Patient Survey reported that 76% of patients and 81% of physicians consider that new treatment options are required (GAPP, 2005). The introduction of novel treatment strategies (such as "add-on" treatments) is a key step for better asthma control ([@b9030]).

Asthma patients tend to use herbal medicines as one of the common therapies of complementary and alternative medicine ([@b9045]). However, these therapies often have insufficient evidence for their effectiveness in asthma. In Saudi Arabia, a questionnaire type study was done by [@b9000] in 200 asthmatic patients. He found that NS is one of the most commonly non-standard therapies used by 10% of the patients.

In this review, we aimed at exploring and assessing the relevant pre-clinical and clinical studies supporting the use of NS in patients with asthma, and evaluating the current evidence to highlight future research priorities.

2. Methods {#s0010}
==========

A literature search for scientific studies published in electronic databases (PubMed, Science Direct, Scopus, and Google Scholar) was done using the terms *Nigella sativa*, Black seed, Thymoquinone and (their pharmacological effects) on asthma. Studies were searched for electronically between the years 1990 and 2017. Retrieved studies were assessed and the data was categorised into preclinical and clinical studies.

3. Results {#s0015}
==========

At least nineteen preclinical studies and seven clinical studies reported the effects of NS in asthma. Details of the retrieved studies are summarised in the following.

3.1. Preclinical studies of *Nigella sativa* in cellular and animal models of asthma {#s0020}
------------------------------------------------------------------------------------

NS and its active compounds thymoquinone, nigellone and α-hederin have been investigated in eighteen whole or cellular animal models and one human cellular model related to asthma. NS oil, thymoquinone or α-hederin showed anti-inflammatory and immunomodulatory effects in seven studies ([@b0005], [@b0055], [@b0105], [@b0170], [@b0180], [@b0185], [@b0195]). NS extracts, thymoquinone or α-hederin demonstrated a bronchodilatory or relaxant effect in six studies ([@b0010], [@b0030], [@b0070], [@b0115], [@b0145], [@b0180]). The anti-histaminic effect was shown in four studies used NS oil/aqueous extract, nigellone or α-hederin ([@b0010], [@b0095], [@b0180], [@b0185]). Pathological improvements were detected by thymoquinone or NS oil in five studies ([@b0045], [@b0080], [@b0105], [@b0130], [@b0195]). The summary of findings of these studies are shown in [Table 1](#t0005){ref-type="table"}.Table 1Effects of NS in pre-clinical studies of asthma.StudiesStudy materialMinimal active doseModelNegative controlPositive controlEffectsNotes & limitationsSerum immunoglobulinsInflammatory mediatorsInflammatory cells, BALFInflammatory cells, lungHistamine releaseBlock H1 receptorsRelaxation of SMOther[@b0095]Nigellone11 µg/mlMixed peritoneal cells of egg albumin induced Wistar ratsN/AN/A↓No control group (without Thymoquinone)[@b0115]NS (70% aqueous-methanol extract)0.1--3.0 mg/mlGuinea pig tracheaN/AN/A+No control group (without Thymoquinone)[@b0030]Thymoquinone50 µMGuinea-pig tracheaN/AN/A++No control group (without Thymoquinone)[@b0080]Aqueous extracts of NS0.3 mlGuinea pig tracheaSalineChlorpheniramine+[@b0170]Thymoquinone3 and 10 µMHuman granulocytesUntreated human granulocytesN/A↓ leukotrienesNo positive control[@b0005]NS fixed oil5 ml/kg/day injected (ip) for 17 daysConalbumin sensitised (CD1) albino miceUntreated miceDexamethasone↓ IgG↓ serum IL-2 & IL-12↓↓ blood eosinophil count[@b0090]NS fixed oil0.3 ml/day for 1 monthOVA sensitised BALB/c miceSalineNo change in IL-4, IL-10 and IFN-γ in splenic mononuclear cellsNo positive control[@b0105]Thymoquinone + 10% DMSO3 mg/kg TQ in 10%DMSO injected (ip) for 5 daysOVA sensitised BALB/c mice and lung cellsSaline + 10% DMSOOVA + 10% DMSO↓ OVA IgE & IgG1↓ IL-4, IL-5, IL-13\
↑ IFN-γ\
in BALF↓ eosinophils↓ eosinophils↓ goblet cells hyperplasia[@b0070]Methanol and dichloromethane extracts of NS-0.8 g% of methanol extract-1.2 g% of dichloromethane extractsGuinea pig tracheaSalineTheophylline+[@b0195]NS fixed oil4 ml/kg/day injected (ip) for 7 daysOVA sensitised E3 ratsSalineN/A↓ Total IgE\
↓ IgG1\
↓ OVA IgG1↓ mRNA expression of IL-4, IL-5, IL-6 and TGF-β1 from lung cells\
↓ nitric oxide in BALF↓ eosinophils, macrophages & lymphocytes↓ eosinophils, macrophages, lymphocytes↓ bronchial and alveolar epithelial hyperplasia\
↓goblet cells and collagen fibresNo positive control[@b0010]Thymoquinone3 mg/kg injected (ip) for 5 days in guinea pig-8 mg/kg injected (ip) for 21 days in ratsOVA sensitised guinea pig trachea\
Mast cells of egg-albumin sensitised ratsSalineN/A↓+No positive control[@b0055]NS fixed oilOral NS oil 4 ml/kg/day for 31 daysOVA sensitised BALB/c miceSalineN/A↓ Total IgE\
↓ OVA IgE & IgG1↑ BALF Th1 cytokines\
↓ BALF Th2 cytokines↓ leukocytes, macrophages & eosinophils↓ Airway hyperresponsivnessNo positive control[@b0185]NS fixed oilOral NS oil 2.5 ml/kg/day for 3 weeksOVA sensitised guinea pig\
Isolated rat peritoneal mast cellsSalineN/A↑ PGE2 in lung tissue\
↓ leukotrienes↓No positive control[@b0145]Fractions of 20% methanolic extract of NS(50, 100, 150, 200 mg/L)Guinea pig tracheaSalineTheophylline+[@b0130]Thymoquinone3 mg/kg/day injected (ip) for 5 daysOVA sensitized BALB/c miceSalineDexamethasone↓ Subepithelial and epithelial hyperplasia\
↓ Number of mast and goblet cells[@b0150]Thymoquinone0.3 mg/kg i.p.OVA-sensitized guinea pigSalineN/A↑ Blood IFN-γ↓ Eosinophil\
↓ Basophils↓ Tracheal responsiveness\
↓ Airway membrane hyperplasia\
↓ Respiratory epithelial denudation\
↓ Cellular infiltration\
↓ EmphysemaNo positive control[@b0180]α-hederin0.3 mg/kg i.p.OVA-sensitized guinea pigSalineThymoquinone↓ Total WBC\
↓ Eosinophils\
↓ Basophils+↓ Tracheal contractile response to histamine[@b0110]α-hederin0.2 mg/kg i.p.OVA-sensitized Wistar ratsSalineThymoquionone↓ IL-13 mRNA\
↓ miRNA-126↓ Pneumocyte and fibroblastic hypertrophy and hyperplasia\
↓ Hyperemia\
↓ Haemorrhage\
↓ Edematous and exudative changes[@b0045]Ethanolic extract of NSOral 500 mg/kg/day for 3 weeksExercise-induced Wistar ratsExercise-induced Wistar rats without NSN/A↓ thickness epithelial bronchi, tunica media (muscle) bronchi, and tunica adventitia bronchi\
↓ number of goblet cellsNo positive control[^1]

Generally, these studies used animal models sensitised with ovalbumin or isolated Guinea pig trachea. Some studies used cellular models such as human granulocytes or animal mast cells. However, these studies had limitations such as the variability of NS preparations used between most them, and absence of control group in some studies ([Table 1](#t0005){ref-type="table"}).

3.2. Clinical studies of *Nigella sativa* in patients with asthma {#s0025}
-----------------------------------------------------------------

Seven clinical studies showed a potential efficacy of NS on asthma outcomes and biomarkers. Three Randomised Double-Blinded Placebo-Controlled Clinical Trials (RDBPCT) and two Randomised Single-Blinded Placebo-Controlled Clinical Trials (RSBPCT) using NS crushed seeds powder or oil/aqueous extract, showed an improvement in clinical symptoms and pulmonary function test in adult asthmatics ([@b0065], [@b0135], [@b0140], [@b0155], [@b0190]). In addition, a reduction of blood eosinophilia was found in RDBPCT by [@b0155]. Also, a decrease in total serum IgE and FeNO, and an increase in serum INF-gamma cytokine were shown in the RSBPCT trial of [@b0190].

A Randomised Double-Blinded Clinical Trial (RDBCT) showed a short bronchodilatory effect in patients with asthma after administration of a single dose of NS ([@b0075]). Two studies used NS in combination with other treatments showed an improvement in ACT and PFT scores ([@b0040], [@b0140]) ([Table 2](#t0010){ref-type="table"}).Table 2Effects of *Nigella sativa* on asthma in clinical studies.Study referenceStudy materialStudy designControlNS doseDurationSampleEffectsAdvantages (+) and limitations (−)SymptomsPulmonary functionBloodOther[@b0190]NS powderRSBPCTPlacebo1 and 2 g/day3 months76 adult asthmatics\
−24 placebo\
−26 (1 g NS)\
−26 (2 g NS)↑ ACT↑ FEV1 (% predicted)\
↑ FEF25-75%\
↑ PEF↓ serum IgE\
↑ serum IFN-γ↓ FeNO+ Large sample size but still comparatively small\
+Longer duration\
−Single-Blinded\
−NS was not chemically characterised[@b0155]NS fixed oilRDBPCTPlacebo1 g/day4 weeks80 adult asthmatics\
−40 active\
−40 placebo↑ ACTNon-significant ↑ FEV1 (% predicted)↓ eosinophils\
No change in serum IgE+The largest study conducted but still a comparatively small\
+NS chemically characterised\
−High standard study design\
−Short duration[@b0140]NS powder\
+ IM (House dust mite)RSBPCTIM + placebo15 mg/kg/day14 weeks31 Child asthmatics\
−8 IM + placebo\
−8 IM + NS\
−8 IM + probiotic\
-7 IM + NS + probiotic↑ ACTNo change in number of Th17 cells−Small sample size\
+NS not chemically characterised and was used in combination\
−Single-blinded\
−Outcomes limited to symptoms only[@b0040]Whole NS seeds + bee honeyNon RCT\
open-labelN/A2 g of NS seeds + 1 tsp honey3 months5 adult asthmatics\
22 non-asthmatics↑ FVC in asthmatics\
↑ PEF in non-asthmatics\
No change in FEV1−Very small sample size\
−NS was not chemically characterised and was used in combination\
−Low standard study design\
−Outcomes were very limited and compared between same group before and after treatment, and not between groups.\
−No symptoms measurement[@b0075]Aqueous extract of NSRDBCT\
crossoverTheophyllineSingle dose of 50 mg/kg150 min15 adult asthmatics↑ FEV1\
↑ MMEF\
↑ PEF+NS was chemically characterised\
−Very small sample size\
−Not placebo controlled\
+Outcomes was limited to pulmonary function[@b0065]Aqueous extract of NSRDBPCTPlacebo15 mL/kg of 0.1 g%3 months29 adult asthmatics\
15 active\
14 controlImproved asthma symptoms↑ FVC\
↑ FEV1\
↑ PEF\
↑ MMEF↓ asthma medication usage.+NS was chemically characterised\
+High standard study design\
−Small sample size\
−Limited outcomes to symptoms and pulmonary function\
−Invalidated symptoms scoring system[@b0135]NS fixed oilRDBPCTPlacebo40--80 mg/kg/day Three times daily3 weeks63 adults:\
−31 allergic rhinitis,\
−3 bronchial asthma,\
−6 atopic eczemaImproved subjective severity of symptoms−↓ eosinophils (not significant)\
−↓ serum IgE (not significant)−Sample of mixed allergic diseases with only 3 asthmatics\
−No pulmonary function measurement\
−Blood biomarkers were not compared between groups\
−limited NS characterisation\
−Unclear and invalidated symptoms scoring system[^2]

However, these clinical trials appeared to have some important limitations ([Table 2](#t0010){ref-type="table"}). In many of these studies, the standard of design was poor as three studies only were RDBPCT. The phytochemical characterisation of the investigational NS product was not shown in many studies. The sample size was comparatively small in most studies. The largest trial by [@b0155] included 80 adult asthmatic patients. The measured outcomes were generally limited to symptoms or pulmonary function in several studies.

Therefore, there is a need for a longer, larger and high standard multicentre clinical trial (more than 80 asthmatic patients) with phytochemically well-characterised NS product. Also, to use validated asthma control measurement tools with consideration of additional asthma outcomes and biomarkers such as FeNO, Sputum eosinophils, total blood eosinophils, total serum IgE, allergen-specific IgE and urinary LTE4 ([@b0200]). Additionally, measuring serum inflammatory cytokines may be worth considering, since asthma is regulated by multiple inflammatory cytokines and some were associated with asthma control ([@b0025]).

4. Conclusion {#s0030}
=============

This literature review showed that various preparations derived from *Nigella sativa* have a potential role for the clinical use in asthma. Preclinical studies of NS preparations showed bronchodilation, anti-histaminic, anti-inflammatory, anti-leukotrienes and immunomodulatory effects in animal or cellular models of asthma. Clinical studies of NS preparations showed an improvement of asthma symptoms control, lung function and asthma biomarkers. However, these studies have study design limitations and limited phytochemical characterisation of NS preparations used. Consequently, the current clinical evidence for the use of NS in patients with asthma is evolving in strength. In future, larger, longer, well-designed clinical trials including additional biomarkers and using phytochemically characterised NS preparation are required for assessing the clinical use of NS in asthma. Eventually, NS may offer a cost-effective and clinically proven effective add-on therapeutic option for asthmatics with fewer side, which may be used as integrative medicine within the Saudi healthcare system and beyond.
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[^1]: ip; intraperitoneal. OVA; ovalbumin. BALF; Bronchoalveolar lavage fluid. N/A; data not included in the original study.

[^2]: RDBPCT; Randomised Double-Blind Placebo-Controlled Trial. RSBPCT; Randomised Single-Blind Placebo-Controlled Trial. RDBCT: Randomised Double-Blind Controlled Trial. ACT; Asthma control test. FEV1; forced expiratory volume in 1 s. FVC; forced vital capacity. MMEF; maximal mid expiratory flow. PEF; peak expiratory flow. Tsp; tea spoonful. FeNO; fractional exhaled nitric oxide. FEF25-75%; mid expiratory flow. IM; Immunotherapy.
